Metagenomi Q3: $184.1M cash, 25% workforce cut, CEO change, MGX-001 data positive

Metagenomi Therapeutics, Inc.

2025-Q3 EPS reported -$1.76 vs consensus -$0.59 ▼ miss (-198.4%)

Cash, equivalents, and marketable securities $184.1M as of Sep 30, 2025; runway extended into Q4 2027.
Workforce reduced by 25%; early discovery and platform research deprioritized.
Jian Irish promoted to CEO; founder Brian Thomas remains on Board; Willard Dere named Board Chair.
MGX-001 hemophilia A preclinical data: curative FVIII activity in NHPs at proposed clinical dose averaging 49%.
Pre-IND meeting expected Q4 2025; IND/CTA submissions targeted for Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.